An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis (NCT01664598), a na phase 3 study. The primary outcome is Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs).

2. Clinical Question

This is principally a descriptive safety question in a selected extension-study population. The primary outcome covers events recorded during treatment and follow-up, with serious events defined by criteria such as death, life-threatening experience, hospitalization, persistent or significant disability, congenital anomaly, or medical significance. Events of special interest included serious infections, including opportunistic infections, and abnormal liver function tests.

The registry also describes efficacy as an area of evaluation and lists secondary outcomes concerning disease activity, joint counts, treatment-free remission, recurrence, pain, and assessments of disease severity. Those outcomes do not change the central interpretive point: without a comparator, changes over time cannot establish how the course of disease or event frequency would have differed under another treatment or no treatment. The study can describe observations among participants in this extension, but it cannot isolate a treatment effect from other explanations.

3. Trial Design

This was a Phase 3, multicenter, open-label, single-arm, long-term extension study of WA19926. Its stated purpose was to describe safety during tocilizumab treatment in people with early, moderate to severe rheumatoid arthritis. Participants were eligible after completing the 104-week WA19926 core study. The registry lists enrollment of 49 and a completed study status.

Participants received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks. There was no randomized allocation and no masking. The study therefore follows one treated group rather than comparing treatment groups under a randomized design. The registry gives a start date of 2012-05 and a primary completion date of 2015-06.

The primary outcome was the percentage of participants with adverse events, serious adverse events, and adverse events of special interest, assessed up to 112 weeks. The registry defines the safety population as the Full Analysis Set, described as all randomized participants enrolled who received at least one dose of tocilizumab. Because the study is also described as single-arm with allocation listed as not applicable, the registry’s wording about randomized participants should be read as a recorded population definition, not as evidence of a randomized comparison.

Secondary outcomes include changes in DAS28-ESR and SDAI, changes in tender and swollen joint counts, treatment-free remission, time to recurrence among participants achieving remission, and participant assessments of disease activity and pain. The registry record does not report the statistical analysis plan or details of how these secondary outcomes were analyzed. Its listed outcomes indicate the breadth of measures collected, but the primary safety summaries should not be interpreted as comparative efficacy findings.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants who completed the 104-week core study WA19926 and could benefit from tocilizumab treatment based on the Investigator's judgment were enrolled in this study.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Full Analysis Set (FAS) included all randomized participants enrolled in the study who received at least one dose of tocilizumab.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Full analysis set (FAS), includes all randomized participants enrolled in the study who received at least one dose of tocilizumab.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs of Special Interest (AESIs), measured over Up to 112 weeks.

The primary endpoint is the percentage of participants experiencing adverse events, serious adverse events, and adverse events of special interest during follow-up of up to 112 weeks. An adverse event is defined as an untoward medical occurrence in a participant given a pharmaceutical product, regardless of whether it was caused by that product. A serious adverse event is defined by seriousness criteria, including death, a life-threatening experience, inpatient hospitalization or prolongation of hospitalization, persistent or significant disability, congenital anomaly or birth defect, or medical significance. The adverse events of special interest listed in the record include serious infections, including opportunistic infections, and abnormal liver function tests.

Counting participants with events is a useful descriptive safety measure because it communicates how many people in the observed group experienced an event during the specified period. The categories differ in clinical seriousness and scope; they should not be treated as interchangeable or added together. A participant may have experienced more than one event, and the record does not give event-level totals for every category in the endpoint description.

This endpoint describes the observed safety experience in the extension group. It does not by itself show that tocilizumab caused an event, or estimate whether event frequency would be higher or lower under a different treatment. The absence of a comparator is particularly important when interpreting events that can also occur as part of illness, background risk, or other care.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a participant-based event percentage describe?

For a binary safety outcome, each participant is classified according to whether an event occurred during the defined observation period. The resulting percentage describes the fraction of the stated safety population with at least one event of that type. It is different from an event rate based on person-time, which accounts for how long each person was observed. The registry’s primary outcome is participant-based, and person-time rates are not reported in the registry record.

Participant-based percentages are straightforward to interpret, but they depend on the event definition, the population included, and the observation window. A broad adverse-event category can include occurrences that are not judged related to treatment. A serious-event category applies seriousness criteria, while an event of special interest is selected for particular monitoring. These groupings can overlap, so they should not be summed as if they represented separate people.

Why does the single-arm design matter?

A single-arm study observes outcomes in one treated group. It can describe what happened to that group, but it cannot directly estimate a treatment contrast against a concurrent control group. In a randomized comparison, random allocation helps balance measured and unmeasured factors between groups on average. That protection against confounding is not available in this design. Differences from past experience or external expectations would not provide the same control, and no such comparison is reported in the registry record.

Open-label treatment means masking was absent. This may influence reporting, evaluation, or decisions about care, especially for outcomes that involve judgment or participant assessment. The registry does not report procedures that would allow readers to assess the impact of this possibility. The absence of masking does not prove that measurements were biased, but it is relevant when interpreting outcomes such as pain and disease-activity assessments.

How should precision be considered?

A confidence interval, in general, describes a range of values compatible with the data under a statistical model and conveys uncertainty around an estimate. The registry record does not report confidence intervals for the primary safety summaries in the registry record. Without an interval, the counts still describe what was observed, but the precision of the underlying event frequency is less directly communicated. Sparse events are especially difficult to estimate precisely because relatively small changes in observed counts can have a substantial effect on the estimated proportion.

Over-dispersion is a general statistical issue that arises when variation in observed outcomes is greater than a chosen model expects. For binary participant-level outcomes, clustering, unequal exposure, or heterogeneity in participants can contribute to variation that a simple model does not capture. The registry record does not report a model for over-dispersion or a cluster-adjusted analysis. Given the single-arm descriptive presentation, the main issue is that the record does not provide a model-based uncertainty analysis to account for such sources of variation.

What do the planning calculations represent?

Planning calculations are hypothetical illustrations, not observed trial outcomes and not evidence of the study’s achieved power. The stated assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a stated fraction of the observed effect. For time-to-event calculations, the stated quantity is a total number of events; other calculations refer to participants per arm.

Those assumptions describe a two-arm planning setup, whereas this extension is a single-arm study with allocation listed as not applicable. They should therefore not be read as the design used to conduct the extension or as a retrospective claim about its ability to detect a treatment difference. Sample size illustrations do not change the interpretation of the observed adverse-event counts. The registry record does not report the trial’s own sample-size justification or statistical plan.

What can be concluded from the listed outcomes?

The primary endpoint names adverse events, serious adverse events, and events of special interest. The record gives safety counts and selected serious-event terms. The secondary outcome list names measures of disease activity, joint counts, remission, recurrence, pain, and disease severity, but the registry record does not report corresponding analysis results in the registry record. Outcome names alone do not establish the direction, size, or precision of an effect.

Multiplicity refers, in general, to the increased chance of at least one false-positive finding when many statistical hypotheses are tested. A prespecified hierarchy or adjustment can address that issue, but the registry record does not report a multiplicity strategy. It also does not report whether interim analyses were conducted. No statistical significance claim should be inferred from the outcome list or from the safety counts alone.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary safety outcome and multiple secondary outcomes spanning disease activity, joint counts, remission, recurrence, pain, and participant assessment of disease severity. When many outcomes are analyzed, multiplicity can increase the chance of at least one apparently notable finding arising by chance. Statistical approaches can address this by controlling the error rate or by specifying a hierarchy of tests. The registry record does not report a multiplicity adjustment, testing hierarchy, or a statistical analysis plan. It also does not report whether interim analyses were conducted.

Missing-data handling is not reported in the registry record. The record does not describe the amount or pattern of missing outcome data, how participants who discontinued were handled, or whether any imputation was used. These details matter because the amount and reasons for missing follow-up can affect the interpretation of observed participant-based event summaries and change-over-time measures. The primary timeframe is up to 112 weeks, but the record does not give participant-level follow-up duration or completeness.

The safety population is described as the Full Analysis Set, including all randomized participants enrolled who received at least one dose of tocilizumab. At the same time, the design is described as single-arm, with allocation listed as not applicable. The posted safety summaries state 49 participants at risk for both serious and other adverse events. The registry record does not provide further detail about population exclusions or reconcile the randomized wording with the single-arm design description.

These reporting gaps limit assessment of potential selection effects and analytical choices. They do not invalidate the recorded counts, but they leave uncertainty about how completely they represent all enrolled participants and how secondary-outcome findings would have been evaluated. No missing-data method or multiplicity procedure should be assumed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: arrhythmia (2.0%), hypertension (2.0%), cholecystitis acute (2.0%), hypertensive crisis (2.0%), pneumonia (2.0%).

The serious adverse-event summary reports 5 participants at risk and 5 affected, with zero deaths recorded. The separate other-adverse-event summary reports 49 at risk and 22 affected. These are distinct categories and should not be added: serious adverse events are defined by seriousness criteria, while the other-adverse-event count is a separate registry summary. A single participant may experience multiple event types, and the counts do not describe the total number of events.

The listed serious-event terms are arrhythmia, hypertension, acute cholecystitis, hypertensive crisis, pneumonia, and jaw abscess, each recorded at 2.0%. These term-level percentages are descriptive. They do not establish that tocilizumab caused the event or indicate how events would compare under another treatment. The primary definition includes adverse events regardless of cause.

The registry describes follow-up of up to 112 weeks, but individual observation time and person-time rates are not reported in the registry record. Counts should therefore be read as the observed safety experience in the reported group, rather than as exposure-adjusted rates or comparative risks. The study’s single-arm design further limits causal interpretation.

12. What the Result Does, and Does Not, Mean

The results describe safety events recorded among participants in a long-term, open-label extension of the WA19926 study. The registry reports 5 participants at risk for serious adverse events and 5 affected, and 49 at risk for other adverse events with 22 affected. It also records zero deaths and lists selected serious-event terms at 2.0% each. These observations are relevant to understanding what was reported during follow-up in this group.

They do not show that tocilizumab caused any particular event. The adverse-event definition includes occurrences regardless of cause, and the study has no concurrent comparator. Without a control group, the results do not establish whether the frequency of events was higher, lower, or similar to what would have occurred under another treatment or without treatment. Nor can the counts alone separate treatment effects from the underlying condition, prior treatment, or other influences.

The record also does not provide confidence intervals or participant-level follow-up durations for these safety summaries. Accordingly, the figures do not convey a complete account of statistical precision or exposure-adjusted event frequency. The listed term percentages describe the registry’s summaries and should not be interpreted as a ranking of clinical importance.

Although the registry includes several secondary outcomes related to disease activity and remission, their analysis results are not reported in the registry record. The outcome list therefore does not establish an efficacy result. Overall, the findings are descriptive evidence about events observed in this extension cohort, not proof of a causal effect, a comparative safety judgment, or a treatment recommendation.

13. Why This Trial Matters Statistically

Long-term extension studies can add descriptive information about events observed while participants continue treatment after a core study. In this record, the extension focuses on tocilizumab exposure in people with early, moderate to severe rheumatoid arthritis who completed WA19926. Its primary safety outcome includes adverse events, serious adverse events, and adverse events of special interest over follow-up of up to 112 weeks. That focus makes clear which safety categories the registry was designed to track.

The statistical value of the record depends on keeping description separate from causal comparison. The study has one open-label treatment group, not a randomized control. Its safety counts document observations in that group, but cannot show how those observations differ from a counterfactual experience. This distinction is important for interpreting all uncontrolled safety evidence, particularly when events may also occur because of the condition or other factors.

The record also illustrates why denominators and outcome definitions matter. Counts of participants affected are not counts of all events, and different adverse-event categories can overlap. The reported observation window gives a maximum timeframe, not a description of each participant’s duration of exposure or follow-up. Those details affect how directly one can compare event frequencies across studies or populations.

Finally, the record names a range of secondary clinical outcomes but does not report their analysis results in the registry record. Separating listed outcomes from reported findings prevents outcome labels from being mistaken for evidence of benefit or harm. The study is most informative as a description of its enrolled extension group, with important limits on precision and comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The single-arm design is the central limitation for interpreting safety. Without a concurrent control group, the study cannot estimate a relative difference in event frequency or distinguish treatment-associated events from events arising for other reasons. Open-label conduct also means participants and study personnel were not masked; the registry record does not describe any procedures used to limit possible influence on reporting or assessment.

The extension population was selected from people who completed the 104-week WA19926 core study and met eligibility requirements. The registry record does not report how this selection affects the representativeness of the extension group compared with people with rheumatoid arthritis who did not enter or complete the core study. Findings therefore apply most directly to the participants described, rather than automatically to a broader population.

Follow-up is stated as up to 112 weeks, and treatment was given for up to 104 weeks. The registry record does not report individual follow-up duration, person-time, or the completeness of observation. It also does not report missing-data methods, confidence intervals for the safety summaries, or a statistical analysis plan. These omissions limit assessment of uncertainty and the handling of participants with incomplete information.

The registry describes the Full Analysis Set using randomized-participant wording even though the extension is identified as single-arm with allocation not applicable. The record does not explain this wording. It reports 49 at risk in each of the serious and other adverse-event summaries but does not give additional details on population construction. Finally, although several secondary outcomes are listed, their results are not reported in the registry record, so they cannot support conclusions about efficacy or changes over time.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis — NCT01664598.
• Registry record last updated 2023-12-11; status last verified 2023-03.
• Results first posted 2023-12-11.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01664598 is a completed Phase 3, multicenter, open-label, single-arm extension study sponsored by Hoffmann-La Roche. It evaluated tocilizumab in participants with early, moderate to severe rheumatoid arthritis who had completed the WA19926 core study. The registry lists enrollment of 49, a start date of 2012-05, and a primary completion date of 2015-06.

Eligible participants received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks. The primary outcome was the percentage of participants with adverse events, serious adverse events, and adverse events of special interest, assessed up to 112 weeks. The safety summaries report 5 participants at risk for serious adverse events, 22 affected among 49 at risk for other adverse events, and zero deaths. The design supports descriptive safety reporting, not a randomized comparison. Secondary outcomes are listed, but their analysis results are not reported in the registry record.